Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

The 1976 movie All the President's Men perhaps provided one of the best three-word investing strategies around: "Follow the money." No, the film didn't use the phrase in the context of investing.

and Lilly’s Mounjaro (tirzepatide) manage sales of $1.4 billion in Q3 2023 – though Zepbound will be the product’s name in weight loss going forwards. Both companies have seen a monumental ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... “As we accelerate our work to discover new medicines for the toughest diseases, we’re ...

Analysts estimate that semaglutide (Ozempic/Wegovy) could generate $28.7 billion, while tirzepatide (Mounjaro/Zepbound ... and exclusive insights on NVO. Our Pro platform offers fair value ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

PHOENIX (AZFamily) — Weight loss drugs have taken the world by storm, but high demand has created a shortage and a new opportunity for compounding pharmacies to make their own version of them at ...